Passive immunotherapy for measles infection - measles (MEV) causes disease worldwide despite efforts towards eradication by vaccine, primarily because IT is readily spread between people

Active Grant Awarded

Award ID
R01AI195589
Recipient
Awarding agency
Obligated
$855,113

Award facts

Assistance listing
93.855 Allergy and Infectious Diseases Research
Completion date 13% complete
Place of performance
New York, NY 10032, USA

Award details come from USAspending.gov.

About this award

The National Institute of Allergy and Infectious Diseases, within the Department of Health and Human Services' National Institutes of Health, awarded The Trustees of Columbia University in the City of New York, doing business as Health Sciences Division, $855,113 on March 27, 2026, under Allergy and Infectious Diseases Research (CFDA 93.855) for Grant R01AI195589. The grant funds identification and production of anti-F neutralizing monoclonal antibodies against the measles virus fusion protein, building a defined cocktail of long-lasting antibodies for future clinical use, and evaluates the protection that anti-F passive immunotherapy provides. Work is aimed at people with impaired cellular immunity who cannot be vaccinated with the live measles vaccine. Aim 1 covers antibody production, selection, and epitope characterization, including a study of viral escape mutants. Aim 2 covers pre-exposure and post-exposure efficacy testing. Work is performed in New York, New York 10032, with a period of performance through March 31, 2031. La Jolla Institute for Immunology, doing business as La Jolla Institute For Allergy & Immunology, is the sub-recipient under sub-award R01AI195589-GG021456-01, dated August 31, 2026. It delivers the protein expression and purification, mouse-derived antibody humanization, epitope mapping and cryo-electron microscopy structural studies, escape-mutant characterization, and purified antibodies for in vivo protection studies.

Description

Acute MEV infection causes immune amnesia, increasing susceptibility to other infectious diseases. In addition, rare but severe neurological complications can develop several years after measles due to persistent MEV infection of the central nervous system (CNS). People with impaired cellular immunity are at increased risk of developing severe measles but often cannot be vaccinated since the vaccine virus itself can lead to fatal illness in this population. There is no specific therapy for acute or persistent MEV manifestations. The only available intervention beside vaccination is hyperimmune sera from vaccinated individuals. The current vaccine elicits antibodies directed against the two envelope glycoproteins, the receptor-binding hemagglutinin and the fusion(F) protein. The antibodies against the hemagglutinin are neutralizing, while current-vaccine-elicited antibodies against the fusion protein are not. This contrasts with wild type induced immunity that elicits effective anti-F neutralizing antibodies. This indicates a clear shortcoming of the current vaccine (i.e., inability to elicit anti-F neutralizing antibodies) that affects the potency of hyperimmune sera obtained from vaccinated people. We have recently identified several anti-F neutralizing antibodies, and we propose to identify several others to build a defined cocktail of long-lasting monoclonal antibodies for future clinical application. The proposed work will address two specific aims: 1. Production and selection of anti-F neutralizing antibodies. 2. Evaluate the protection afforded by anti-F protein passive immunotherapy. Our application will significantly impact the growing number of severely immune- compromised individuals who cannot be vaccinated with the current live MEV vaccine and would benefit from a defined cocktail of neutralizing monoclonal antibodies.

Subawards

Subrecipient Amount Awarded
La Jolla Institute For Immunology Aim 1: Production and selection of anti-F neutralizing antibodies. Aim 1.1: Developing neutralizing mAbs against MeV F. a) Protein Production and… $274,500

Quick answers

Who received award R01AI195589?

R01AI195589 was awarded to The Trustees Of Columbia University In The City Of New York by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on March 27, 2026.

How much is award R01AI195589 worth?

$855,113 has been obligated on R01AI195589.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award